Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
J Immunother Cancer. 2022 Nov;10(11):e005018. doi: 10.1136/jitc-2022-005018.
J Immunother Cancer. 2022.
PMID: 36323431
Free PMC article.
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo.
Deronic A, Nilsson A, Thagesson M, Werchau D, Enell Smith K, Ellmark P.
Deronic A, et al. Among authors: thagesson m.
Cancer Immunol Immunother. 2021 Dec;70(12):3629-3642. doi: 10.1007/s00262-021-02932-5. Epub 2021 May 5.
Cancer Immunol Immunother. 2021.
PMID: 33948686
Free PMC article.
Item in Clipboard
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
Kvarnhammar AM, Veitonmäki N, Hägerbrand K, Dahlman A, Smith KE, Fritzell S, von Schantz L, Thagesson M, Werchau D, Smedenfors K, Johansson M, Rosén A, Åberg I, Winnerstam M, Nyblom E, Barchan K, Furebring C, Norlén P, Ellmark P.
Kvarnhammar AM, et al. Among authors: thagesson m.
J Immunother Cancer. 2019 Apr 11;7(1):103. doi: 10.1186/s40425-019-0570-8.
J Immunother Cancer. 2019.
PMID: 30975201
Free PMC article.
Item in Clipboard
Cite
Cite